H-ras oncogene mutation in dedifferentiated chondrosarcoma:: Polymerase chain reaction-restriction fragment length polymorphism analysis

被引:19
作者
Sakamoto, A
Oda, Y
Adachi, T
Oshiro, Y
Tamiya, S
Tanaka, K
Matsuda, S
Iwamoto, Y
Tsuneyoshi, M
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Fukuoka 8128582, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Higashi Ku, Fukuoka 8128582, Japan
[3] Matsuyama Red Cross Hosp, Dept Pathol, Matsuyama, Ehime, Japan
关键词
dedifferentiated chondrosarcoma; conventional chondrosarcoma; H-ras mutation; PCR-RFLP;
D O I
10.1038/modpathol.3880313
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Dedifferentiated chondrosarcomas, which are known for their poor prognosis, are characterized by conventional chondrosarcoma with high-grade anaplastic components. Activating mutations in ms genes are a common genetic abnormality in human malignancies. The presence of point mutations at codons 12 and 13 of the H-ras gene was studied in 20 formalin-fixed paraffin-embedded chondrosarcomas, comprising 11 cases of conventional chondrosarcoma (six Grade 1 cases and five Grade 2 cases) and nine cases of dedifferentiated chondrosarcoma, using polymerase chain reaction-restriction fragment length polymorphism and direct sequencing analysis. H-ras mutations were only seen in two out of the nine cases of dedifferentiated chondrosarcoma (2/9, 22%) and they were not seen in any of the cases of conventional chondrosarcoma (0/11, 0%). Dedifferentiated chondrosarcomas had a worse prognosis than conventional chondrosarcomas (P <.01); among the patients with dedifferentiated chondrosarcomas, those with H-ras mutation (n = 2) tended to have a worse prognosis than those without (n = 7), although the difference was not statistically significant (P = 0.068). Our results would seem to suggest that H-ras mutation may occur during the course of dedifferentiation and may also have some effect on malignant potential.
引用
收藏
页码:343 / 349
页数:7
相关论文
共 47 条
[1]  
[Anonymous], 1998, BONE TUMORS
[2]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[3]   AMPLIFICATION OF C-MYC ONCOGENE AND ABSENCE OF C-HA-RAS POINT MUTATION IN HUMAN BONE SARCOMA [J].
BARRIOS, C ;
CASTRESANA, JS ;
RUIZ, J ;
KREICBERGS, A .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1993, 11 (04) :556-563
[4]   ABERRANT REGULATION OF RAS PROTEINS IN MALIGNANT-TUMOR CELLS FROM TYPE-1 NEUROFIBROMATOSIS PATIENTS [J].
BASU, TN ;
GUTMANN, DH ;
FLETCHER, JA ;
GLOVER, TW ;
COLLINS, FS ;
DOWNWARD, J .
NATURE, 1992, 356 (6371) :713-715
[5]  
Bohle RM, 1996, AM J PATHOL, V148, P731
[6]  
BOS JL, 1989, CANCER RES, V49, P4682
[7]  
Bovée JVMG, 1999, J PATHOL, V189, P454, DOI 10.1002/(SICI)1096-9896(199912)189:4<454::AID-PATH467>3.0.CO
[8]  
2-N
[9]  
BRIDGE JA, 1994, AM J PATHOL, V144, P215
[10]  
CAMPANACCI M, 1979, Italian Journal of Orthopaedics and Traumatology, V5, P331